AR109209A1 - Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas - Google Patents
Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativasInfo
- Publication number
- AR109209A1 AR109209A1 ARP170102166A ARP170102166A AR109209A1 AR 109209 A1 AR109209 A1 AR 109209A1 AR P170102166 A ARP170102166 A AR P170102166A AR P170102166 A ARP170102166 A AR P170102166A AR 109209 A1 AR109209 A1 AR 109209A1
- Authority
- AR
- Argentina
- Prior art keywords
- prevention
- treatment
- pharmaceutical composition
- neurodegenerative diseases
- radotinib
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160097863 | 2016-08-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109209A1 true AR109209A1 (es) | 2018-11-07 |
Family
ID=61073817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102166A AR109209A1 (es) | 2016-08-01 | 2017-07-31 | Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas |
Country Status (4)
| Country | Link |
|---|---|
| KR (1) | KR102421303B1 (fr) |
| AR (1) | AR109209A1 (fr) |
| TW (1) | TW201808294A (fr) |
| WO (1) | WO2018026150A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102618168B1 (ko) * | 2018-07-06 | 2023-12-27 | 일양약품주식회사 | 프리온 질환의 예방 또는 치료를 위한 약제학적 조성물 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3134922A1 (fr) * | 2012-05-02 | 2013-11-07 | Georgetown University | Traitement d'une alpha-synucleinopathie au moyen d'inhibiteurs de la tyrosine kinase |
| US20140127157A1 (en) * | 2012-11-05 | 2014-05-08 | Novartis Ag | Antiviral activity of tyrosine kinase inhibitors against hepatitus c virus |
-
2017
- 2017-07-31 TW TW106125709A patent/TW201808294A/zh unknown
- 2017-07-31 KR KR1020170096803A patent/KR102421303B1/ko active IP Right Grant
- 2017-07-31 WO PCT/KR2017/008229 patent/WO2018026150A1/fr active Application Filing
- 2017-07-31 AR ARP170102166A patent/AR109209A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180015085A (ko) | 2018-02-12 |
| TW201808294A (zh) | 2018-03-16 |
| WO2018026150A1 (fr) | 2018-02-08 |
| KR102421303B1 (ko) | 2022-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| MX2020013881A (es) | Compuestos inhibidores de bcl-xl y conjugados de anticuerpo-farmaco que los incluyen. | |
| DOP2017000178A (es) | Inhibidores selectivos de bace1 | |
| CR20160538A (es) | Combinación | |
| UY37879A (es) | Compuestos de bisamida que activan el sarcómero y sus usos | |
| CO2017013293A2 (es) | Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina | |
| CO2017001875A2 (es) | Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor bace | |
| MX2021006901A (es) | Agentes terapeuticos para enfermedades neurodegenerativas. | |
| CL2016001587A1 (es) | Derivado basado en 1,2-naftoquinona y método de preparación del mismo. | |
| CL2016001756A1 (es) | Preparación farmacéutica que comprende 0,001-0,003 pv de 6-4-pirazol-1-ilbencilpiridin-3-ilsulfonilaminometilpiridin-2-ilaminoacetato de isopropilo o una sal del mismo uso para el tratamiento o prevención de glaucoma o hipertensión ocular. | |
| CR20150505A (es) | Derivado de dihidropiridazin-3,5-diona | |
| SV2016005313A (es) | Derivados de carboxamida | |
| EP3440094A4 (fr) | Inhibiteur de la localisation mitochondriale de tdp -43 pour le traitement d'une maladie neurodégénérative | |
| ZA201805407B (en) | Composition for the prevention or treatment of neurodegenerative diseases. | |
| CO2019013254A2 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| EP3708161A4 (fr) | Agent visant à améliorer un dysfonctionnement mitochondrial, agent préventif ou thérapeutique pour des maladies ou des symptômes provoqués par un dysfonctionnement mitochondrial, et leurs applications | |
| CR20180111A (es) | Agentes antibacteriales que comprenden una pirazino[2,3-b] [1,4] oxazin-3-ona o un sistema de anillos relacionado | |
| IT201700121764A1 (it) | Composizione per il trattamento e/o la prevenzione di patologie neurodegenerative. | |
| CR20170125A (es) | Composición farmacéutica sólica que comprende amlodipina y losartán | |
| AR109209A1 (es) | Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas | |
| MY182634A (en) | Pharmaceutical containing sodium-dependent phosphate transporter inhibitor | |
| MX2020003427A (es) | Agentes terapeuticos para enfermedades neurodegenerativas. | |
| MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. | |
| BR112018015483A2 (pt) | formulações farmacêuticas sólidas estáveis que contêm 2-(2-nitro-4-trifluorometil-benzoil)-1,3 -ciclo-hexanodiona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |